13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-11-06 Event 2026-11-06 SEC 0001104659-26-124003 →

BAKER BROS. ADVISORS LP → Madrigal Pharmaceuticals, Inc. MDGL

Stake: 9.99% Shares: 2,330,144 CUSIP: 558868105 Class: Common Stock, $0.0001 par value per share
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 32/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: -1.3%
  • Filer track record (4 filings): 0% 90d win rate, +0.0% 90d edge
  • High conviction ownership stake (10.0%)
  • Held by 1 tracked 13F institutional manager
  • 15 NPORT-P mutual funds holding CUSIP
  • Elevated short days-to-cover (7.2 DTC)

Item 4 — Purpose of Transaction

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: This Amendment No. 5 is being filed to report the acquisition of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer (by means of open market purchases, privately negotiated purchases, conversion of some or all of the Convertible Preferred (as defined in Item 5), exercise of some or all of the Prefunded Warrants (as defined in Item 5) subject to limitations described in Item 5, or otherwise) or to dispose of some or all of the securities of the Issuer under their control.

Cross-References

Insider Activity (last 365d)
1 transaction
0 buys · 1 sales · 0 awards/exercises
Issuer Cluster
8 13D/G filings on this issuer
7 other filings besides this one
Filer Track Record
68 filings by this filer
67 other filings in the data moat
Short Interest · settle 2026-10-15
DTC 7.24
2,194,545 shares short · -8.4% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $79.63M
Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-06-01 Soergel David officer Sale 1,042 $495.74 $517K

Other 13D/G Filings on Madrigal Pharmaceuticals, Inc.

FiledFormFilerStakeShares
2023-10-05 SC BAKER BROS. ADVISORS LP — — view →
2021-12-07 SC BAY CITY CAPITAL LLC — — view →
2020-09-08 SC BAY CITY CAPITAL LLC — — view →
2020-06-01 SC BAY CITY CAPITAL LLC — — view →
2019-10-17 SC FRIEDMAN PAUL A — — view →
2019-10-17 SC BAY CITY CAPITAL LLC — — view →
2019-10-17 SC Taub Rebecca — — view →

Other Filings by BAKER BROS. ADVISORS LP

FiledFormIssuerStakeShares
2026-09-30 SCHEDULE 13D/A Kodiak Sciences Inc. 35.00% 22,049,297 view →
2026-09-16 SCHEDULE 13D/A BeOne Medicines Ltd. — 115,457,154 view →
2026-08-11 SCHEDULE 13D/A Replimune Group, Inc. 11.80% 11,075,336 view →
2026-07-16 SCHEDULE 13D/A Celcuity Inc. 9.99% 4,877,963 view →
2026-07-16 SCHEDULE 13G Celcuity Inc. — — view →
2026-06-15 SCHEDULE 13D/A BeOne Medicines Ltd. BEIGF 8.00% 115,457,154 view →
2026-05-26 SCHEDULE 13D/A Kiniksa Pharmaceuticals International, plc KNSA 7.00% 3,231,181 view →
2026-05-11 SCHEDULE 13D/A Incyte Corp INCY — 30,865,077 view →
2025-06-30 SCHEDULE Kymera Therapeutics, Inc. KYMR 9.50% 6,666,540 view →
2024-10-08 SC Kiniksa Pharmaceuticals International, plc KNSA — — view →
2024-06-14 SC INCYTE CORP INCY — — view →
2023-12-18 SC Seagen Inc. — — view →
2023-10-10 SC Neoleukin Therapeutics, Inc. NGNE — — view →
2023-10-05 SC MADRIGAL PHARMACEUTICALS, INC. MDGL — — view →
2023-07-19 SC Neoleukin Therapeutics, Inc. NGNE — — view →
2023-05-24 SC ACADIA PHARMACEUTICALS INC ACAD — — view →
2023-05-24 SC Prelude Therapeutics Inc PRLD — — view →
2023-05-03 SC Seagen Inc. — — view →
2023-03-15 SC INCYTE CORP INCY — — view →
2023-03-13 SC Seagen Inc. — — view →
Showing 20 of 67

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →